New search | Conferencedetail
Print view
 
 

First EASL NAFLD Summit: Diagnosis and pharmacotherapy of NASH

evvnt Platform / evvnt
Conference themes
NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages.
Professional congress organizer (PCO)
European Association for the Study of the Liver (EASL)
Notes
Speakers: Prof. Ali Canbay (Germany), Prof. Claus Hellebrand (Germany), Prof. Wing-Kin Syn (United States), Prof. Michael Trauner (Austria)
 

Enquiries and Registration:

https://go.evvnt.com/125207-1
Ms. EASL The Home of Hepatology
 
Categories
General Medicine
Languages
English
Congress fees
EASL Member (VAT exckusive): EUR 450 , Non Member (VAT exckusive): EUR 550 , Young Investigator and Nurse (EASL Member - VAT exckusive): EUR 150 , Young Investigator and Nurse (Non Member - VAT exckusive): EUR 200
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

AGEM - Arbeitsgemeinschaft Ethnomedizin e. V.Helix - Forschung & Beratung WienEuropean Public Health Association (EUPHA)Charité International AcademynewTreeCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioFFG - 7. EU-RahmenprogrammÄrztekammer für Wien

Facebook

Give us your professional opinion

Start survey

Start survey